Could a competitor lowering prices eat into Hims & Hers market share? Shares of Hims & Hers (HIMS -7.54%) fell as much as 8% on Tuesday and closed at their low for the day after news broke that Eli Lilly (LLY 0.42%) lowered the price for a key weight loss drug. Eli Lilly's shot at Hims & Hers The big news on Tuesday was an announcement that Eli Lilly will sell the weight loss drug Zepbound through its direct-to-consumer website at a 50% discount to the previous price. A 2.5 milligram single-dose vial will c ...

After a strong start to the year, the stock is down 30% since June. In this video, I will be talking about Hims & Hers' (HIMS -0.60%) recent earnings report and explain why there has been some weakness in the stock. Check out the short video to learn more, consider subscribing, and click the special offer link below. *Stock prices used were from the trading day of Aug. 21, 2024. The video was published on Aug. 22, 2024. ...

greg801/E+ via Getty Images In an odd twist, Hims & Hers Heath, Inc. (NYSE:HIMS) reported booming sales, yet the stock was actually sold hard following earnings. Management of the online ir and view of a new receinting met (1 rosemans) representation weight lose world beath was man hall belowing chamilies. Mangules. Ho downline, Maligenten dio ouline, Malin Ti DAILY | --- | --- | --- | --- | --- | |-------|------------------------|---------|-------|---------------| | | | | | | | | finviz | | | | | | HIMS Au ...

PM Images/DigitalVision via Getty Images Markets appear to have shaken off the fears stemming from U.S. recession talk and the unwinding of the Japan carry trade, but a number of stocks still remain well off their recent highs. Hims & Hers Health, Inc. (NYSE:HIMS), the maker and distributor of generic medicines, is one of the most notable names in this bucket. The stock has been rocked after reporting Q2 results, primarily on concerns that its revenue projections for its GLP-1 weight loss compounds are over ...

Daniel Grizelj Introduction Hims & Hers Health (NYSE:HIMS) has had an outstanding year so far, as the stock price is up 87.73% YTD. Q4'23 earnings gave investors a lot of confidence going forward, as the company exceeded expectations and raised its guidance. Q1'24 earnings also received a great reception, with the company posting great results once again. Weeks later, the company announced it would start selling compounded GLP-1 agonists to subscribers. Investors and the market responded well, as the stock ...

Wall Street is missing the forest for the trees, and the opportunity is enormous. The injectable weight loss drugs known as GLP-1 agonists have taken the world by storm. And the stocks of the companies making the drugs have crushed the market over the past couple of years. However, an industrywide shortage for the drugs opened the door for companies like Hims & Hers Health (HIMS -0.83%) to compete by offering lower-priced compounded versions mixed up by their teams. Hims & Hers stocks took flight once the c ...

A small telemedicine company just entered the weight loss race. Medications used for weight loss, such as Ozempic, Wegovy, Mounjaro, and Zepbound, are taking over the pharmaceutical industry. While Eli Lilly and Novo Nordisk are the big players in diabetes and obesity care thanks to their glucagon-like peptide-1 (GLP-1) agonists, there are a number of companies looking to dethrone the industry stalwarts. For the most part, competitors are investing hefty sums into research and development to bring their own ...

Growth is set to accelerate starting next quarter, powered by its GLP-1 offering. Although the company reported strong second-quarter results and raised its guidance, shares of Hims & Hers Health (HIMS 0.69%) slipped immediately after its earnings announcement. Nonetheless, the stock has been a strong performer this year, up over 80%. Let's take a look at the telehealth company's most recent results, and decide whether it still makes sense to buy the stock on this recent pullback. Surging revenue Hims & Her ...

Hims & Hers Health, Inc. (HIMS) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future. Over the past month, shares of this company have returned -24.7%, compared to the Zacks S&P 500 composite's -4.5% change. During this period, the Zacks Medical Info Systems industry, which Hims & Hers Health falls in, has gained 7.4%. The key question now is: What could be the stock's ...

Don't overlook the 52% growth in the second quarter. Hims & Hers (HIMS -5.38%) reported another outstanding quarter in the second quarter of 2024 as members, revenue, and net income hit all-time records. So, why did the stock drop? Travis Hoium digs into the results and what the market was looking for in this video. *Stock prices used were end-of-day prices of Aug. 6, 2024. The video was published on Aug. 6, 2024. ...